2nd Quarter - Report
STRATEGIC MARKETING INNOVATIONS for TONIX PHARMACEUTICALS
Client
Income
$40,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN WOLFE | — |
Defense DEF
Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN WOLFE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.